FDA warned Tramadol US for selling unapproved, misbranded opioid and benzodiazepine drugs, including tramadol, oxymorphone, and alprazolam, over the internet.
What happened
FDA reviewed Tramadol US's websites and found the company offering unapproved and misbranded opioid and benzodiazepine drugs to U.S. consumers. The letter cites "Tramadol 100mg," "Opana ER 15mg," and "Yellow Xanax Bars" (alprazolam) offered "Without Prescription." FDA said no approved applications are in effect for the tramadol and oxymorphone products.
What FDA found
Sold tramadol and oxymorphone products that FDA has not approved.
FD&C Act section 505(a) [21 U.S.C. § 355(a)]; section 301(d) [21 U.S.C. § 331(d)]The prescription drug labeling did not give adequate directions for a layperson to use the drugs safely.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]Offered prescription drugs, including alprazolam, for sale without a prescription.
FD&C Act section 503(b)(1) [21 U.S.C. § 353(b)(1)]; section 301(k) [21 U.S.C. § 331(k)]Caused misbranded drugs to be introduced into interstate commerce by offering them for sale.
FD&C Act section 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA asks Tramadol US to stop offering unapproved and misbranded drugs to U.S. consumers and to reply in writing within 15 working days with steps taken to fix the violations and prevent recurrence.
Who should pay attention
- online pharmacies and website operators
- companies whose prescription drug brands are sold or named online
- clinicians and consumers managing opioid or benzodiazepine risks
This is a summary. Read the original letter on fda.gov.